메뉴 건너뛰기




Volumn 37, Issue 3, 2014, Pages 151-161

Near-real-time monitoring of new drugs: An application comparing prasugrel versus clopidogrel

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; NEW DRUG; PRASUGREL; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

EID: 84896095687     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0136-0     Document Type: Article
Times cited : (15)

References (32)
  • 2
    • 69949122850 scopus 로고    scopus 로고
    • Prasugrel in clinical practice
    • Bhatt DL. Prasugrel in clinical practice. N Engl J Med. 2009;361:940-2.
    • (2009) N Engl J Med , vol.361 , pp. 940-942
    • Bhatt, D.L.1
  • 3
    • 34447547659 scopus 로고    scopus 로고
    • Developments in post-marketing comparative effectiveness research
    • DOI 10.1038/sj.clpt.6100249, PII 6100249
    • Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther. 2007;82:143-56. (Pubitemid 47075343)
    • (2007) Clinical Pharmacology and Therapeutics , vol.82 , Issue.2 , pp. 143-156
    • Schneeweiss, S.1
  • 4
    • 33748680917 scopus 로고    scopus 로고
    • Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: Design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)
    • DOI 10.1016/j.ahj.2006.04.012, PII S0002870306003486
    • Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627-35. (Pubitemid 44396884)
    • (2006) American Heart Journal , vol.152 , Issue.4 , pp. 627-635
    • Wiviott, S.D.1    Antman, E.M.2    Gibson, C.M.3    Montalescot, G.4    Riesmeyer, J.5    Weerakkody, G.6    Winters, K.J.7    Warmke, J.W.8    McCabe, C.H.9    Braunwald, E.10
  • 5
    • 81355139590 scopus 로고    scopus 로고
    • Assessing the comparative effectiveness of newly marketed medications: Methodological challenges and implications for drug development
    • Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011;90:777-90.
    • (2011) Clin Pharmacol Ther , vol.90 , pp. 777-790
    • Schneeweiss, S.1    Gagne, J.J.2    Glynn, R.J.3    Ruhl, M.4    Rassen, J.A.5
  • 6
    • 78149345321 scopus 로고    scopus 로고
    • Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices
    • Resnic FS, Gross TP, Marinac-Dabic D, et al. Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices. JAMA. 2010;304:2019-27.
    • (2010) JAMA , vol.304 , pp. 2019-2027
    • Resnic, F.S.1    Gross, T.P.2    Marinac-Dabic, D.3
  • 7
    • 84859852184 scopus 로고    scopus 로고
    • Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples
    • Wahl PM, Gagne JJ, Wasser TE, et al. Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Drug Saf. 2012;35:407-16.
    • (2012) Drug Saf , vol.35 , pp. 407-416
    • Wahl, P.M.1    Gagne, J.J.2    Wasser, T.E.3
  • 8
    • 84862626391 scopus 로고    scopus 로고
    • Active safety monitoring of newly marketed medications in a distributed data network: Application of a semi-automated monitoring system
    • Gagne JJ, Glynn RJ, Rassen JA, et al. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012;92:80-6.
    • (2012) Clin Pharmacol Ther , vol.92 , pp. 80-86
    • Gagne, J.J.1    Glynn, R.J.2    Rassen, J.A.3
  • 9
    • 84857042212 scopus 로고    scopus 로고
    • Active safety monitoring of new medical products using electronic healthcare data: Selecting alerting rules
    • Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012;23:238-46.
    • (2012) Epidemiology , vol.23 , pp. 238-246
    • Gagne, J.J.1    Rassen, J.A.2    Walker, A.M.3    Glynn, R.J.4    Schneeweiss, S.5
  • 10
    • 0142157169 scopus 로고    scopus 로고
    • Evaluating Medication Effects Outside of Clinical Trials: New-User Designs
    • DOI 10.1093/aje/kwg231
    • Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-20. (Pubitemid 37323253)
    • (2003) American Journal of Epidemiology , vol.158 , Issue.9 , pp. 915-920
    • Ray, W.A.1
  • 11
    • 77956625112 scopus 로고    scopus 로고
    • A basic study design for expedited safety signal evaluation based on electronic healthcare data
    • Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19:858-68.
    • (2010) Pharmacoepidemiol Drug Saf , vol.19 , pp. 858-868
    • Schneeweiss, S.1
  • 12
    • 77953517347 scopus 로고    scopus 로고
    • Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population
    • Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf. 2010;19:596-603.
    • (2010) Pharmacoepidemiol Drug Saf , vol.19 , pp. 596-603
    • Wahl, P.M.1    Rodgers, K.2    Schneeweiss, S.3
  • 13
    • 0036792795 scopus 로고    scopus 로고
    • Validating administrative data in stroke research
    • Tirschwell DL, Longstreth WT Jr. Validating administrative data in stroke research. Stroke. 2002;33:2465-70.
    • (2002) Stroke , vol.33 , pp. 2465-2470
    • Tirschwell, D.L.1    Longstreth Jr., W.T.2
  • 14
    • 0035500992 scopus 로고    scopus 로고
    • Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data
    • DOI 10.1093/aje/154.9.854
    • Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-64. (Pubitemid 33000813)
    • (2001) American Journal of Epidemiology , vol.154 , Issue.9 , pp. 854-864
    • Schneeweiss, S.1    Seeger, J.D.2    Maclure, M.3    Wang, P.S.4    Avorn, J.5    Glynn, R.J.6
  • 15
    • 79956217851 scopus 로고    scopus 로고
    • A combined comorbidity score predicted mortality in elderly patients better than existing scores
    • Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64:749-59.
    • (2011) J Clin Epidemiol , vol.64 , pp. 749-759
    • Gagne, J.J.1    Glynn, R.J.2    Avorn, J.3    Levin, R.4    Schneeweiss, S.5
  • 16
    • 77951622706 scopus 로고
    • The central role of the propensity score in observational studies for causal effects
    • Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
    • (1983) Biometrika , vol.70 , pp. 41-55
    • Rosenbaum, P.R.1    Rubin, D.B.2
  • 17
    • 67651042983 scopus 로고    scopus 로고
    • High-dimensional propensity score adjustment in studies of treatment effects using health care claims data
    • Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512-22.
    • (2009) Epidemiology , vol.20 , pp. 512-522
    • Schneeweiss, S.1    Rassen, J.A.2    Glynn, R.J.3    Avorn, J.4    Mogun, H.5    Brookhart, M.A.6
  • 18
    • 84856034091 scopus 로고    scopus 로고
    • Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system
    • Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):41-9.
    • (2012) Pharmacoepidemiol Drug Saf , vol.21 , Issue.SUPPL. 1 , pp. 41-49
    • Rassen, J.A.1    Schneeweiss, S.2
  • 19
    • 84879890519 scopus 로고    scopus 로고
    • Confounding adjustment in comparative effectiveness research conducted within distributed research networks
    • Toh S, Gagne JJ, Rassen JA, Fireman BH, Kulldorff M, Brown JS. Confounding adjustment in comparative effectiveness research conducted within distributed research networks. Med Care. 2013;51:S4-10.
    • (2013) Med Care , vol.51
    • Toh, S.1    Gagne, J.J.2    Rassen, J.A.3    Fireman, B.H.4    Kulldorff, M.5    Brown, J.S.6
  • 20
    • 79958845225 scopus 로고    scopus 로고
    • Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples
    • Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011;173:1404-13.
    • (2011) Am J Epidemiol , vol.173 , pp. 1404-1413
    • Rassen, J.A.1    Glynn, R.J.2    Brookhart, M.A.3    Schneeweiss, S.4
  • 21
    • 84862230912 scopus 로고    scopus 로고
    • An event-based approach for comparing the performance of methods for prospective medical product monitoring
    • Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012;21:631-9.
    • (2012) Pharmacoepidemiol Drug Saf , vol.21 , pp. 631-639
    • Gagne, J.J.1    Walker, A.M.2    Glynn, R.J.3    Rassen, J.A.4    Schneeweiss, S.5
  • 23
    • 79955553942 scopus 로고    scopus 로고
    • Availability of comparative efficacy data at the time of drug approval in the United States
    • Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ. Availability of comparative efficacy data at the time of drug approval in the United States. JAMA. 2011;305:1786-9.
    • (2011) JAMA , vol.305 , pp. 1786-1789
    • Goldberg, N.H.1    Schneeweiss, S.2    Kowal, M.K.3    Gagne, J.J.4
  • 24
    • 84867177857 scopus 로고    scopus 로고
    • Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
    • Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297-309.
    • (2012) N Engl J Med , vol.367 , Issue.14 , pp. 1297-1309
    • Roe, M.T.1    Armstrong, P.W.2    Fox, K.A.3
  • 25
    • 84856050291 scopus 로고    scopus 로고
    • Design considerations in an active medical product safety monitoring system
    • Gagne JJ, Fireman B, Ryan PB, et al. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):32-40.
    • (2012) Pharmacoepidemiol Drug Saf , vol.21 , Issue.SUPPL. 1 , pp. 32-40
    • Gagne, J.J.1    Fireman, B.2    Ryan, P.B.3
  • 26
    • 82555196119 scopus 로고    scopus 로고
    • Full coverage for preventive medications after myocardial infarction
    • Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088-97.
    • (2011) N Engl J Med , vol.365 , pp. 2088-2097
    • Choudhry, N.K.1    Avorn, J.2    Glynn, R.J.3
  • 28
    • 84859004974 scopus 로고    scopus 로고
    • Pragmatic randomised trials using routine electronic health records: Putting them to the test
    • Staa TP, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ. 2012;344:e55.
    • (2012) BMJ , vol.344
    • Staa, T.P.1    Goldacre, B.2    Gulliford, M.3
  • 29
    • 84881502708 scopus 로고    scopus 로고
    • You can observe a lot (about medical products) by watching (those who use them)
    • Gagne JJ. You can observe a lot (about medical products) by watching (those who use them). Epidemiology. 2013;24:700-2.
    • (2013) Epidemiology , vol.24 , pp. 700-702
    • Gagne, J.J.1
  • 30
    • 84884290134 scopus 로고    scopus 로고
    • Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research
    • Gagne JJ, Bykov K, Willke RJ, Kahler KH, Subedi P, Schneeweiss S. Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. Value Health. 2013;16:1054-62.
    • (2013) Value Health , vol.16 , pp. 1054-1062
    • Gagne, J.J.1    Bykov, K.2    Willke, R.J.3    Kahler, K.H.4    Subedi, P.5    Schneeweiss, S.6
  • 32
    • 84862932391 scopus 로고    scopus 로고
    • The U.S. Food and Drug Administration's Mini-Sentinel program: Status and direction
    • Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):1-8.
    • (2012) Pharmacoepidemiol Drug Saf , vol.21 , Issue.SUPPL. 1 , pp. 1-8
    • Platt, R.1    Carnahan, R.M.2    Brown, J.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.